

PRECEPTORSHIP PROGRAMME

Gastric Cancer

Multidisciplinary management,
standards of care, therapeutic
targets and future perspectives

**ESMO VIRTUAL
PRECEPTORSHIP**

22-23 OCTOBER 2021

Co-Chairs

Florian Lordick, Germany

Elizabeth Smyth, United Kingdom

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME

GASTRIC CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

22-23 October 2021

CO-CHAIRS: Florian Lordick, Germany
Elizabeth Smyth, United Kingdom

SPEAKERS: Fatima Carneiro, Portugal
Christelle de la Fouchardiere, France
Tania Fleitas Kanonnikoff, Spain
Valentina Gambardella, Spain
Karin Haustermans, Belgium
Magnus Nilsson, Sweden
Hanneke van Laarhoven, Netherlands

LEARNING OBJECTIVES

- To learn about the fundamentals of pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment of gastric cancer
- To learn about advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered CEST (Central European Summer Time)

Friday, 22 October 2021

15:00-15:10 10'	Opening and welcome	
10'	Welcome from ESMO and introduction	Florian Lordick, DE Elizabeth Smyth, UK
15:10-17:20 130'	SESSION 1 Localized gastroesophageal adenocarcinomas	Chair/Moderator: Florian Lordick, DE
25'	Pathology assessment of gastric and junctional adenocarcinomas	Fatima Carneiro, PT
25'	The role of surgery in localized gastric and junctional cancers	Magnus Nilsson, SE
25'	Developments in radiotherapy for localized gastric and junctional cancers	Karin Haustermans, BE
10'	Discussion	Faculty
16:35-16:45	Break	
25'	Neoadjuvant and adjuvant therapy for localized gastric and junctional cancers	Christelle de la Fouchardiere, FR
10'	Discussion	Faculty
17:20-18:20 60'	SESSION 2 Cases discussion of localized disease	Chair/Moderator: Elizabeth Smyth, UK
4x15'	4 x Participants clinical case discussion	Faculty

Saturday, 23 October 2021

15:00-17:15 135'	SESSION 3 Treatment for advanced gastroesophageal adenocarcinomas	Chair/Moderator: Elizabeth Smyth, UK
20'	First line treatment for HER2 non amplified advanced gastroesophageal adenocarcinomas	Florian Lordick, DE
20'	HER2 amplified GEA - challenges and new options	Tania Fleitas Kanonnikoff, ES
20'	Second line treatment and beyond for advanced gastroesophageal adenocarcinomas (including chemo and targeted agents)	Hanneke van Laarhoven, NL
10'	Discussion	Faculty
16:10-16:20	Break	
25'	Novel Immunotherapy approaches for localized and advanced gastroesophageal adenocarcinomas	Elizabeth Smyth, UK
20'	Novel precision medicine approaches for localized and advanced gastroesophageal adenocarcinomas	Valentina Gambardella, ES
10'	Discussion	Faculty

17:15-18:15 60'	SESSION 4 Cases discussion of advanced disease	Chair/Moderator: Florian Lordick, DE
4x15'	4 x Participants clinical case discussion	Faculty
18:15-18:25 10'	Future outlook, conclusion and farewell	Florian Lordick, DE Elizabeth Smyth, UK

Note: Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion